Announcement of new products and name change to Preora Healthcare coincides with initiation of Series A financing round. (Oct. 24, 2017) Click to view
Preora has received two prestigious recognitions that acknowledge the promise of its PWS NanoctyologyTM platform to make dramatic improvements in cancer survival rates. (Sept. 21, 2017) Click to view
New executive provides broad expertise commercializing medical device products. (Sept. 20, 2017) Click to view
Novel sample preparation technology identified as an important innovation for company’s cancer screening tests, and for external clinicians and researchers. (Aug. 11, 2017) Click to view
Company takes critical step in the commercialization of its PWS NanocytologyTM cancer screening technology platform. (Aug. 3, 2017) Click to view
Preora Diagnostics President & CEO John Hart participates in conference highlighting how impact investing can advance leading-edge technologies under development in Chicago. (March 22, 2017) Click to view
Award follows Wall Street Journal recognition as a new technology worth watching. (Nov. 29, 2016) Click to view
New Lung Cancer Screening Data from Preora Diagnostics Published in Peer-Reviewed Biomedical Optics Express
Successful optimization study moves company forward toward commercialization of PWS Nanoctyology technology platform. (Sept. 22, 2016) Click to view.
In the first episode of its “Amazing Things” podcast series, the national United for Medical Research coalition featured Northwestern Professor and Preora Chairman Vadim Backman, who explains why PWS Nanocytology is a breakthrough method for detecting cancer earlier than ever. (Sept. 13, 2016) Click to view
Company also participating in RESI and Cavendish conferences in September 2016.
Click here to read the full story.
AdvaMed 2016 Innovation Showcase